BioRestorative Therapies, Inc. filed 4 current reports with the SEC under Item 5.02, which covers directors and officers leaving or being appointed, the latest on 2026-09-11. Between them they name 5 people, with 5 appointments and 1 departure. Each change below is quoted from the filing and linked to it.
Every change, newest first
Reported
On September 4, 2026, BioRestorative Therapies, Inc. (the " Company ") received a notice of resignation from Mr. Silva from his employment with the Company, including as the Company's Vice President of Research and Development, and from each other position (if any) he held as an officer of the Company, effective immediately.
Appointed: Mika Grasso, Chief Executive Officer
On August 26, 2026, the Board appointed Mika Grasso as the Company's Interim Chief Executive Officer, effective immediately.
Appointed: Steven Brown, Chairman of the Board
On September 1, 2026, the Board also appointed Mr. Brown as Chairman of the Board.
Departing: David Rosa, Director
On July 11, 2026, David Rosa resigned as a director of the Company and from each committee of the Board of Directors of the Company (the "Board") on which he served, including the Compensation Committee, effective immediately.
Appointed: Katharyn Field, Chief Executive Officer, effective 2026-07-13
Effective July 13, 2026, the Board appointed Katharyn Field, a director of the Company, as an officer of the Company and, by unanimous written consent, the Board confirmed Ms. Field's appointment as Chief Executive Officer and President of the Company and, on an interim basis pending completion of the Board's search for a permanent Chief Financial Officer, as interim Chief Financial Officer, Treasurer and Secretary of the Company.
Appointed: Esha Randhawa, Director
On July 13, 2026, the Board elected Esha Randhawa as a Class II director of the Company, with a term expiring at the Company's 2028 annual meeting of stockholders, filling the vacancy created by Mr. Rosa's resignation, and, on July 14, 2026, the Board elected Steven Brown as a Class III director of the Company, with a term expiring at the Company's 2026 annual meeting of stockholders, filling the vacancy created by Mr. Alstodt's cessation of service as a director.
Appointed: Mika Grasso, Director
(d) On June 12, 2026, pursuant to the Revolving Loan Agreement, the remaining members of the Company's Board of Directors (the "Board") appointed Mika Grasso, Katharyn Field and Jatinder Dhaliwal (collectively, the "New Directors"), designees of the Lender, as directors of the Company.
Find people with the same kind of experience as the Chief Executive Officer at BioRestorative Therapies, Inc., with the record behind each one.
Find candidates like Chief Executive Officer at BioRestorative Therapies, Inc.New leaders review vendors and budgets in their first months. Get an alert the next time BioRestorative Therapies, Inc. is in the news or changes leadership.
Get an alert when BioRestorative Therapies, Inc. changes leadershipTools for this story
Each opens in a new tab, filled in for BioRestorative Therapies, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.